Uveal melanoma (UM) technology platforms serve patients facing the most common primary intraocular malignancy in adults — a rare ocular melanoma arising from melanocytes of the uveal tract (choroid in approximately 90 percent of cases, ciliary body in 6 percent, iris in 4 percent), affecting approximately 5 to 7 per million adults annually in the United States, with a biology fundamentally distinct from cutaneous melanoma: driven not by UV-induced BRAF mutations but by activating mutations in GNAQ or GNA11 in approximately 80 to 85 percent of cases, with monosomy 3 (loss of chromosome 3) and chromosome 8q gain conferring the highest metastatic risk, and a dismal metastatic prognosis where hepatic metastasis occurs in 50 percent of patients by five years and median overall survival after metastasis diagnosis has historically been 12 to 14 months despite immunotherapy — a biology that makes monitoring and early detection of metastatic recurrence the central clinical challenge of UM survivorship. Ocular oncologists, radiation oncologists delivering proton beam therapy or plaque brachytherapy, vitreoretinal surgeons, medical oncologists, hepatic surgeons, and interventional radiologists depend on these platforms to manage the specialized ocular treatment — local ophthalmic tumor control through proton beam radiotherapy, Ruthenium-106 or Iodine-125 plaque brachytherapy, or enucleation for large tumors — to coordinate the genetic risk stratification that drives surveillance intensity based on chromosome 3 status and gene expression profile (GEP) class, to manage the surveillance imaging protocols targeting hepatic metastasis with MRI of the liver, and to deliver systemic therapy for metastatic UM including the bispecific T-cell engager tebentafusp (the first FDA-approved therapy for HLA-A*02:01-positive metastatic UM), clinical trial enrollment, and liver-directed therapies including hepatic arterial infusion, chemoembolization, and isolated hepatic perfusion. When a UM tech platform fails during ocular treatment planning, chromosome 3 risk stratification documentation review, hepatic surveillance MRI result integration, or tebentafusp infusion safety monitoring, the metastatic recurrence risk and the narrow therapeutic window of this highly lethal ocular malignancy are placed at further peril: ocular oncologists cannot access plaque brachytherapy dosimetry records when verifying local treatment adequacy, medical oncologists cannot retrieve HLA typing confirmation needed before tebentafusp administration, and hepatic surgery teams cannot access surveillance imaging documenting liver metastasis burden before planning liver-directed therapy.
Uveal melanoma technology platforms — whether serving academic ocular oncology programs with dedicated UM multidisciplinary teams, proton therapy centers delivering charged particle radiotherapy for globe-preserving UM treatment, radiation oncology programs managing episcleral plaque brachytherapy, vitreoretinal surgery programs handling UM enucleation, medical oncology programs administering tebentafusp or clinical trial therapy for metastatic UM, or hepatic surgery and interventional radiology programs delivering liver-directed therapy — must maintain the availability and performance standards that reflect the genetic risk stratification complexity of primary UM management, the hepatic surveillance intensity required to detect early metastatic recurrence, and the tebentafusp administration requirements of this immune-based therapy in patients with a specific HLA type. This guide explains why UM tech platforms require dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the diagnostic, local treatment, surveillance, and systemic therapy complexity of uveal melanoma care.
Why UM Tech Platforms Require Specialized Monitoring Attention
UM management is characterized by specialized ocular oncology diagnostic and treatment approaches that require integration of ophthalmic imaging, radiation dosimetry, and genetic risk stratification; an intensive hepatic surveillance program that is the primary driver of post-treatment follow-up care and determines when systemic therapy is initiated; and systemic therapy in the metastatic setting that requires HLA typing verification, infusion safety monitoring, and liver-directed therapy coordination. Technology failures in these domains can compromise local treatment safety documentation, delay risk stratification, disrupt surveillance scheduling, or interrupt systemic therapy safety monitoring.
Ocular oncology diagnostic and treatment platforms document primary tumor characterization and local therapy. UM diagnosis requires ophthalmic examination by ocular oncology specialists with wide-angle fundus photography, B-scan ultrasonography for tumor thickness measurement, fluorescein angiography, OCT, and MRI of the orbit for large tumors or when extraocular extension is suspected. Tumor thickness (basal diameter and apical height), location relative to the optic disc and fovea, ciliary body involvement, and extraocular extension determine eligibility for globe-preserving versus enucleation therapy. Proton beam radiotherapy — delivered as five fractions over five to seven days — requires precise surgical clip placement on the sclera to define the tumor margins for radiation targeting; episcleral plaque brachytherapy requires ophthalmic dosimetry planning to deliver the prescribed dose to the tumor apex while protecting the lens, optic nerve, fovea, and optic disc. Platforms managing ophthalmic imaging records, ultrasonography tumor measurement documentation, surgical clip placement operative records, radiation treatment planning and dosimetry records, and post-treatment ophthalmic surveillance imaging support the ocular oncology team managing primary UM. Monitor ocular oncology diagnostic and treatment platforms during business hours with immediate alerting when treatment planning or dosimetry records are required.
Genetic risk stratification platforms drive post-treatment surveillance intensity. Risk stratification for metastatic potential in UM is based on chromosome 3 status (monosomy 3 versus disomy 3), chromosome 8q gain, chromosome 6p gain as a favorable marker, and gene expression profiling (GEP) — the commercially available Class 1A, Class 1B, and Class 2 classification from Castle Biosciences' DecisionDx-UM assay — which stratifies 5-year metastatic risk as approximately 2 percent (Class 1A, disomy 3), 21 percent (Class 1B, disomy 3), and 72 percent (Class 2, often with monosomy 3). FISH or SNP array cytogenetic analysis of fine needle aspiration biopsy or enucleation specimens provides chromosome 3 status. Platforms managing cytogenetic analysis results, GEP classification documentation, risk stratification tier assignment, and surveillance protocol assignment based on risk tier support the UM team in individualizing the surveillance intensity — more frequent hepatic MRI in Class 2 patients — that is the primary intervention reducing time to metastatic detection. Monitor genetic risk stratification result delivery during business hours with immediate alerting when surveillance protocol assignment depends on the result.
Hepatic surveillance imaging platforms detect metastatic recurrence. Hepatic MRI with gadolinium contrast is the standard surveillance imaging for UM metastasis detection — typically performed every 6 months for Class 1 patients and every 3 to 6 months for Class 2 patients — because the liver is the dominant site of first metastatic spread in UM due to hematogenous dissemination through the uveal vasculature to the hepatic portal circulation, and isolated hepatic metastasis may be amenable to liver-directed therapy. CT of the chest is performed concurrently to detect pulmonary or extrahepatic metastasis. Platforms managing hepatic MRI scheduling, gadolinium contrast administration records, MRI result integration and comparison with prior surveillance imaging, extrahepatic disease assessment, and hepatic oncology consultation records when metastasis is detected support the UM surveillance program. Monitor hepatic surveillance imaging platforms during business hours with immediate alerting when MRI results require review for active staging decisions.
Systemic therapy administration platforms govern tebentafusp and clinical trial treatment. Tebentafusp-tebn (Kimmtrak), approved by the FDA in January 2022 for HLA-A02:01-positive adults with unresectable or metastatic uveal melanoma, is the first therapy to demonstrate overall survival benefit in metastatic UM — the Phase 3 IMCgp100-202 trial showed one-year overall survival of 73 percent versus 59 percent with investigator's choice. Tebentafusp requires HLA-A02:01 typing confirmation before therapy initiation (approximately 40 to 50 percent of metastatic UM patients are eligible), weekly intravenous infusion administration, mandatory 16-hour post-infusion monitoring period for the first three infusions to assess for cytokine release syndrome (CRS) — the most common adverse event, occurring in approximately 89 percent of patients with most events Grade 1-2 — and monitoring for rash, pyrexia, hypotension, and edema. Platforms managing HLA typing confirmation records, CRS grading documentation, tebentafusp infusion scheduling and administration records, safety monitoring documentation for mandatory post-infusion observation periods, dose modification records for CRS or rash toxicity, and REMS program compliance documentation support the medical oncology team administering tebentafusp. Monitor tebentafusp administration and post-infusion safety monitoring at 1-minute intervals during infusion clinic hours and mandatory observation periods.
Liver-directed therapy platforms coordinate hepatic metastasis treatment. For UM patients with isolated or predominantly hepatic metastasis, liver-directed therapies include hepatic arterial infusion (HAI) chemotherapy, transarterial chemoembolization (TACE), transarterial radioembolization (TARE) with Y-90 microspheres, isolated hepatic perfusion (IHP), percutaneous hepatic perfusion (PHP), and surgical hepatic metastasectomy for resectable oligometastatic disease. These approaches require hepatic surgery, interventional radiology, and medical oncology collaboration with tumor board review, hepatic arterial anatomy assessment, liver function testing, and careful sequencing with systemic tebentafusp therapy. Platforms managing liver-directed therapy tumor board documentation, hepatic arterial anatomy imaging, liver function test records for procedural safety assessment, and interventional radiology or hepatic surgery operative records support the multidisciplinary team managing hepatic UM metastasis. Monitor liver-directed therapy coordination platforms during business hours.
What to Monitor on a UM Tech Platform
Ocular Oncology Diagnostic and Local Treatment Documentation
Monitor ophthalmic imaging record delivery, ultrasonography tumor measurement documentation, surgical clip placement operative records, proton beam radiotherapy or episcleral plaque brachytherapy dosimetry records, and post-treatment ophthalmic surveillance imaging during business hours. Alert immediately on failures when radiation dosimetry or treatment planning documentation is required.
Genetic Risk Stratification and GEP Classification
Monitor cytogenetic analysis result delivery (chromosome 3 FISH or SNP array), GEP classification documentation (DecisionDx-UM Class 1A, 1B, or 2), risk stratification tier assignment, and surveillance protocol scheduling based on risk tier during business hours. Alert immediately on failures when surveillance protocol assignment depends on risk classification.
Hepatic Surveillance Imaging
Monitor hepatic MRI scheduling and result integration, gadolinium contrast administration records, comparison imaging availability for radiologist review, extrahepatic staging imaging, and hepatic oncology consultation documentation during business hours. Alert immediately on failures during active staging or restaging reviews.
Tebentafusp Administration and CRS Monitoring
Monitor HLA-A*02:01 typing confirmation records, tebentafusp infusion scheduling, CRS grading documentation, mandatory post-infusion observation period safety monitoring records, rash and pyrexia toxicity documentation, and REMS compliance records at 1-minute intervals during infusion clinic hours and mandatory observation windows. Alert immediately on failures on scheduled tebentafusp infusion days.
Liver-Directed Therapy Coordination
Monitor liver-directed therapy tumor board documentation, hepatic arterial anatomy imaging records, liver function test integration for procedural safety, and interventional radiology or hepatic surgery operative records during business hours. Alert on sustained failures when liver-directed therapy planning is active.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. UM programs coordinate across ocular oncology, radiation oncology, ophthalmic surgery, medical oncology, hepatic surgery, interventional radiology, radiology, genetics, pharmacy, and pathology — authentication failures lock every specialist out of local treatment, surveillance, and systemic therapy records simultaneously.
SSL Certificates Across All Domains
Monitor SSL certificate expiry across all clinical interfaces, patient portals, radiation oncology systems, and laboratory result ingestion endpoints. Certificate errors require immediate IT resolution before scheduled tebentafusp infusion or liver-directed therapy planning sessions.
HIPAA and Ocular Oncology Compliance Considerations
UM technology platforms handle sensitive PHI spanning ocular oncology examination and imaging records, genetic risk stratification results from chromosome analysis and GEP, radiation therapy dosimetry and treatment records, systemic therapy administration and CRS safety monitoring documentation, hepatic surveillance imaging records, and liver-directed therapy operative records. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components.
For platforms managing tebentafusp REMS program documentation and CRS post-infusion monitoring records, access controls must ensure that medical oncologists, infusion pharmacy staff, and safety monitoring personnel can access records at the clinical moment required. HL7 FHIR standards support imaging result, laboratory, and pathology report exchange across the multidisciplinary UM team. Radiation therapy proton beam planning systems often operate on dedicated networks — monitoring should confirm availability of both clinical documentation platforms and the integration endpoints connecting proton therapy information systems to oncology EHR platforms. Availability monitoring documentation is relevant to demonstrating that platform reliability controls match the specialized local treatment, genetic risk stratification, hepatic surveillance, and systemic therapy safety monitoring requirements of UM care programs.
Alerting Strategy for UM Tech Platforms
Immediate tebentafusp infusion-day alert: HLA typing confirmation, CRS pre-treatment safety verification, and mandatory post-infusion observation monitoring on scheduled tebentafusp infusion days. Alert the moment safety verification data is unavailable.
Immediate ocular treatment planning alert: Proton beam dosimetry or plaque brachytherapy planning records when treatment simulation or delivery depends on the documentation.
Immediate genetic risk stratification alert: Cytogenetic and GEP result delivery when surveillance protocol assignment is pending.
Immediate hepatic staging alert: Hepatic MRI results when active staging decisions for liver-directed therapy or systemic therapy initiation are under review.
Sustained-failure alert (10–15 minutes): Liver-directed therapy coordination documentation, post-treatment ophthalmic surveillance imaging, and hepatic metastasis response assessment imaging.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms UM platform availability from the geographies where specialized proton therapy centers, ocular oncology programs, academic medical centers with tebentafusp infusion capability, and hepatic surgery programs access the system — important for UM patients who travel to specialized centers for local ocular treatment and may receive surveillance and systemic therapy at regional oncology programs.
Status Page for UM Care Team Communication
A real-time status page gives UM program coordinators, ocular oncology scheduling staff, proton therapy center staff, infusion pharmacy personnel, hepatic surgery teams, and tumor board participants immediate platform visibility without requiring inbound IT support contact. During a documentation platform outage when a medical oncologist is retrieving HLA-A*02:01 typing confirmation records before proceeding with a scheduled tebentafusp infusion for a patient with metastatic UM, a status page enables immediate notification to the infusion clinic and oncology team and activation of manual HLA record retrieval backup protocols rather than delaying or canceling therapy.
Include the status page URL in infusion clinic downtime procedures, ocular oncology backup protocols, proton therapy center documentation fallback workflows, and hepatic surveillance imaging notification procedures.
Vigilmon Setup for UM Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Tebentafusp HLA confirmation and infusion safety (infusion days) | 1 min | Slack + PagerDuty (infusion hours) | | CRS grading and post-infusion observation monitoring | 1 min | Slack + PagerDuty (infusion and observation hours) | | Ocular treatment planning and dosimetry records | 2 min | Slack (business hours, immediate on planning days) | | Genetic risk stratification and GEP results | 2 min | Slack (business hours, immediate on assignment days) | | Hepatic surveillance MRI results | 2 min | Slack (business hours, immediate on staging review days) | | Liver-directed therapy coordination | 2 min | Slack (business hours) | | Post-treatment ophthalmic surveillance | 2 min | Slack (sustained failure 15 min) | | Extrahepatic staging imaging | 2 min | Slack (business hours) | | Patient portal (surveillance and treatment access) | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure tebentafusp HLA typing confirmation and CRS safety monitoring at 1-minute intervals aligned with infusion clinic hours and mandatory post-infusion observation windows
- Add ocular treatment planning and radiation dosimetry monitoring with immediate alerting when proton beam or plaque brachytherapy documentation is required
- Configure genetic risk stratification and GEP result delivery monitoring with immediate alerting when surveillance protocol assignment is pending
- Add hepatic surveillance MRI result integration monitoring with immediate alerting during active staging reviews for liver-directed therapy or systemic therapy initiation decisions
- Configure liver-directed therapy coordination monitoring during active hepatic metastasis treatment planning periods
- Add post-treatment ophthalmic surveillance and extrahepatic staging imaging monitoring with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, patient-facing, radiation oncology, and laboratory integration domains
- Add the status page URL to infusion clinic downtime procedures, ocular oncology backup protocols, and hepatic surveillance notification workflows
Conclusion
Uveal melanoma technology platforms are embedded in clinical decisions where genetic risk stratification by chromosome 3 status and GEP class determines surveillance intensity for a malignancy where 50 percent of patients develop hepatic metastasis, hepatic MRI surveillance every 3 to 6 months for high-risk patients is the primary intervention enabling early liver-directed therapy or systemic therapy initiation, tebentafusp HLA verification and CRS post-infusion monitoring protect patients receiving the only therapy to demonstrate overall survival benefit in metastatic UM, and proton beam radiotherapy dosimetry documentation ensures that globe-preserving local treatment achieves tumor control while protecting the optic nerve and fovea — all in a malignancy where the transition from locally controlled primary ocular tumor to uniformly lethal hepatic metastatic disease represents one of oncology's most stark prognostic transitions, and where the precision of genetic risk stratification, the regularity of hepatic surveillance, and the safety of tebentafusp administration are the clinical anchors of modern UM management. A genetic risk stratification platform unavailable when a surveillance protocol must be assigned for a newly treated UM patient, a hepatic surveillance MRI result system that delays metastasis documentation when a hepatic oncologist is planning liver-directed therapy, or a tebentafusp administration safety platform that prevents access to CRS grading records during a mandatory post-infusion observation period — these are not IT incidents. They are clinical disruptions in the care of patients whose metastatic recurrence risk is defined by genetic markers that require accurate documentation, whose survival may depend on hepatic surveillance that detects liver metastasis early enough to enable liver-directed therapy, and whose tebentafusp safety monitoring must function without interruption during the cytokine release syndrome observation windows of the first three infusion cycles.
Uptime monitoring gives UM tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to ocular oncology programs, proton therapy centers, academic medical oncology teams, and compliance auditors that the platform's operational reliability matches the genetic risk stratification precision, hepatic surveillance regularity, and tebentafusp safety monitoring demands of this rare but devastatingly lethal intraocular malignancy.
Start monitoring your UM tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #uvealmelanoma #UM #ocularoncology #intraocularmelanoma #choroidalmelanoma #protontherapy #plaquebrachytherapy #tebentafusp #Kimmtrak #hepaticmetastasis #liverdirectedtherapy #CRS #HLA #GEP #chromosome3 #healthtech #digitalhealth #uptime #hipaa #cancertech #sre